TITLE lecturer Institution. Presenter Disclosure Information.

Slides:

Advertisements

Similar presentations

When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1.

Advertisements

ACME Marketing Plan Presented by Sydney Division [Slide 1]

In austere financial times, which procedures should be rationed and who should decide? Jason Yuen Final year medical student – University of Oxford Professor.

Patient Demographics: AGE: 67 year old Gender: Female Cardiac risk Factors: Hypertension, Diabetes, hypercholesterolemia Clinical Presentation: NSTEMI.

5S CLÍNICA MÉDICA (MH) 306 A. 5S CLÍNICA MÉDICA (MH) 306 B.

V.: 9/7/2007 AC Submit1 Statistical Review of the Observational Studies of Aprotinin Safety Part I: Methods, Mangano and Karkouti Studies CRDAC and DSaRM.

Trileaflet Aortic Valve. Management strategy for patients with chronic severe aortic regurgitation. Preoperative coronary angiography should be performed.

A multicenter, randomized, prospective DKCRUSH-III study

AKI Definitions Stuart L. Goldstein, MD Professor of Pediatrics University of Cincinnati College of Medicine Director, Center for Acute Care Nephrology.

CCE 4: Bridging Clinical Expertise Using Predictive Computational Cancer Models CRC screening and follow-up – Semi-mechanistic model of CRC development.

Complication after Procedure Resident Name, MD Attending Name, MD Institution Morbidity & Mortality Conference Date.

Use of Psoas Muscle Size as a Frailty Assessment Tool for Open and Transcatheter Aortic Valve Replacement Raghavendra Paknikar BS Jeffrey Friedman BS David.

Ischaemic Heart Disease for the GP Chris Tracey GPVTS.

Poster Title Author(s) Institution Poster Title Author(s) Institution INTRODUCTION HISTORY SIMSCON th South Indian Medical Students’ Conference,

Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and.

Findings suggest: -Although the participants reported high medication compliance at baseline, improvement was noted. -The improvement in medication adherence.

Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.

Fabiani & Budhrani Heart Institute Commissioned on June 4, 2006.

Will my Glaucoma patient lose vision ?

Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.

Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Lung Cancer Case Presentation Presenter Date:. Educational Objectives.

The following personal financial relationships with commercial interests relevant to this presentation existed during the past 12 months: DISCLOSURES.

Lessons Learned from the Society of Thoracic Surgeons (STS) Congenital Database September 25, 2015 Robert J. Dabal, MD Associate Professor of Surgery.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.

Hexabrix Key Clinical Review Liss, 2006 Mid-Year Sales Meeting Bloomington, IN July 13 th – 17 th.

Presentation Title Speaker Name. Conflict of Interest Disclosures for Speakers 1. I do not have any potential conflicts to disclose. 2. I wish to disclose.

Standardizing Handoff

Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.

State the Medical Research Topic Give a short description of the purpose of the research topic and what the teaching materials will cover.

Risk Stratification in Unstable Angina Prospective Validation of the Braunwald Classification JAMA, January 11, 1995-Vol.273,No. 2.

Clinical Documents Progress Reports. General Characteristics Usually cover one month of therapy Usually cover 6-8 sessions Audience is wider than that.

Insights from the PROMISE Trial Neha J. Pagidipati, MD MPH; Kshipra Hemal; Adrian Coles, PhD; Daniel B. Mark, MD MPH; Rowena J. Dolor, MD MHS; Patricia.

Strategies to Improve Inadequate Guide Catheter Support John S Douglas Jr MD S Tanveer Rab MD Emory University School of Medicine Atlanta Georgia Sunday.

Multivessel Coronary Artery Disease

(ARM 2004) 1 INNOVATIVE STATISTICAL APPROACHES IN HSR: BAYESIAN, MULTIPLE INFORMANTS, & PROPENSITY SCORES Thomas R. Belin, UCLA.

Article Title Resident Name, MD SVCH6/13/2016 Journal Club.

CoRPS Center of Research on Psychology in Somatic diseases Brief Depression Screening with the PHQ-2 Predicts Poor Prognosis following PCI with Drug-Eluting.

Introduction Data Statistical Methods Table 1: Prevalence of Prior Hip Fracture and Incidence of New Hip Fractures and Fractures of Any Type.

Viewing submission summaries in eResearch IRBMED Institutional Review Board University of Michigan Medical School

Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:

TAVI „Catch me if you can!“

PCI in Patients With Diabetes: Show Me the Data

بسم الله الرحمن الرحیم.

Part III Lessons Learned: A Master Class in High-Sensitivity Troponin A Global Perspective.

Risk Stratification in PAH: What Do the Latest Data Suggest?

The ABCs of AF.

Epidemiology Venous Pathophysiology Etiology.

دانشگاه شهیدرجایی تهران

تعهدات مشتری در کنوانسیون بیع بین المللی

Risk Stratification in CAD and PAD

بسمه تعالی کارگاه ارزشیابی پیشرفت تحصیلی

Updated Guideline Recommendations for the Definitive Diagnosis of Unexplained Syncope.

Your Poster’s Title Goes Here Name of Presenter Name of Institution

Managing Multiple Myeloma in the Elderly

Insert title of your case here

Shodmonov M.. The main goal of the work Analysis.

Name of Hospital Presenter: Consultant Physician: Presentation Date:

PRESENTER NAME PRESENTER INSTITUTION

PRESENTER NAME PRESENTER INSTITUTION

We have created this PowerPoint Template as a guide

REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:

The ABCs of AF.

Your Poster’s Title Goes Here names go here institution names go here

11th INTRODUCTION HISTORY Poster Title : Author(s) : Institution :

TITLE OF THE PRESENTATION

PRESENTER NAME PRESENTER INSTITUTION

Abstract or Presentation Title Presenters Name Presenters Institution

Presentation transcript:

TITLE lecturer Institution

Presenter Disclosure Information

CASE SUMMARY Patient demographics Age Gender Risk factors Past medical history Clinical presentation Sympotam CCS class Cardiac markers Echo Renal function

BASELINE ANGIOGRAPHY

 Euro score  SYNTAX score  NERS score  。。。。 RISK STRATIFICATION

STRATEGY Reason/guidelinePossible problem/choice

STEP 1 Instrument/device

STEP 2 Instrument/device

STEP 3 Instrument/device

FINAL ANGIOGRAPHY

POST PROCEDURE Sympotam CCS class Cardiac markers Echo Renal function

FOLLOW-UP ANGIOGRAPHY

Summarize ／ Take Home Message

Thanks for Your Attention ！